Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.

Tollefson GD, Sanger TM.

Am J Psychiatry. 1997 Apr;154(4):466-74.

PMID:
9090332
[PubMed - indexed for MEDLINE]
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
[PubMed - indexed for MEDLINE]
3.

Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?

Tollefson GD, Andersen SW.

J Clin Psychiatry. 1999;60 Suppl 5:23-9; discussion 30. Review.

PMID:
10192404
[PubMed - indexed for MEDLINE]
4.

[Clinical efficacy of olanzapine].

Yui K.

Nihon Shinkei Seishin Yakurigaku Zasshi. 1999 Jul;19(3):101-10. Review. Japanese.

PMID:
10495984
[PubMed - indexed for MEDLINE]
5.
6.

The negative component in schizophrenia.

Möller HJ.

Acta Psychiatr Scand Suppl. 1995;388:11-4. Review.

PMID:
7541597
[PubMed - indexed for MEDLINE]
7.

Effects of D-cycloserine on negative symptoms in schizophrenia.

Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP.

Schizophr Res. 2004 Dec 1;71(2-3):239-48. Review.

PMID:
15474895
[PubMed - indexed for MEDLINE]
8.

[Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms].

Petit M, Langlois S.

Encephale. 1996 Jun;22 Spec No 2:13-8. Review. French.

PMID:
8767036
[PubMed - indexed for MEDLINE]
9.

Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia.

Singh V, Singh SP, Chan K.

Int J Neuropsychopharmacol. 2010 Mar;13(2):257-71. doi: 10.1017/S1461145709990654. Epub 2009 Sep 24. Review.

PMID:
19775502
[PubMed - indexed for MEDLINE]
10.

The psychopathology of schizophrenia: an integrated view on positive symptoms and negative symptoms.

Möller HJ.

Int Clin Psychopharmacol. 1995 Sep;10 Suppl 3:57-64. Review.

PMID:
8866766
[PubMed - indexed for MEDLINE]
11.

Dopamine agonists in schizophrenia: a review.

Benkert O, Müller-Siecheneder F, Wetzel H.

Eur Neuropsychopharmacol. 1995;5 Suppl:43-53. Review.

PMID:
8775758
[PubMed - indexed for MEDLINE]
12.

Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy.

Spencer EK, Campbell M.

Schizophr Bull. 1994;20(4):713-25. Review.

PMID:
7701278
[PubMed - indexed for MEDLINE]
Free Article
13.

Benzodiazepines in the treatment of schizophrenia: an updated survey.

Lingjaerde O.

Acta Psychiatr Scand. 1991 Nov;84(5):453-9. Review.

PMID:
1685616
[PubMed - indexed for MEDLINE]
14.

Recognizing primary vs secondary negative symptoms and apathy vs expression domains.

Kirkpatrick B.

J Clin Psychiatry. 2014 Apr;75(4):e09. doi: 10.4088/JCP.13049tx3c. Review.

PMID:
24813410
[PubMed - indexed for MEDLINE]
15.

Residual and negative symptoms in treatment with neuroleptics.

Kane JM.

Psychopharmacol Ser. 1993;10:131-7. Review. No abstract available.

PMID:
8103222
[PubMed - indexed for MEDLINE]
16.

Dopamine autoreceptor agonists in the treatment of schizophrenic disorders.

Wetzel H, Benkert O.

Prog Neuropsychopharmacol Biol Psychiatry. 1993 Jul;17(4):525-40. Review.

PMID:
8103233
[PubMed - indexed for MEDLINE]
17.

[Chemotherapies of negative schizophrenia].

Petit M, Dollfus S.

Encephale. 1991 Jul-Aug;17(4):241-5. Review. French.

PMID:
1683624
[PubMed - indexed for MEDLINE]
18.

[The placebo effect: general information and specificities in psychiatry (depression and schizophrenia)].

Corfmat J, Januel D, Braha S, Moulier V.

Encephale. 2012 Feb;38(1):50-7. doi: 10.1016/j.encep.2011.01.010. Epub 2011 Apr 8. Review. French.

PMID:
22381724
[PubMed - indexed for MEDLINE]
19.

The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)?

Schmidt-Hansen M, Le Pelley M.

Cogn Neuropsychiatry. 2012 Nov;17(6):473-505. doi: 10.1080/13546805.2012.667202. Epub 2012 Mar 26. Review.

PMID:
22443090
[PubMed - indexed for MEDLINE]
20.

Prevalence and longitudinal stability of negative symptoms in healthy participants.

Emmerson LC, Ben-Zeev D, Granholm E, Tiffany M, Golshan S, Jeste DV.

Int J Geriatr Psychiatry. 2009 Dec;24(12):1438-44. doi: 10.1002/gps.2284. Review.

PMID:
19388007
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk